A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Y-2 Sublingual Tablet in Healthy Subjects

Trial Profile

A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Y-2 Sublingual Tablet in Healthy Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Y-2 (Primary)
  • Indications Intracranial haemorrhages; Stroke
  • Focus Adverse reactions
  • Sponsors YenePharma
  • Most Recent Events

    • 17 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top